Skip to main content
XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD logo

XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD — Investor Relations & Filings

Ticker · 600721 ISIN · CNE000000KQ1 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,250 across all filing types
Latest filing 2026-05-12 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600721

About XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD

http://www.xjbhc.net/

XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD. is a specialized pharmaceutical technology enterprise primarily engaged in pharmaceutical research and development (R&D) and contract research organization (CRO) services. The company provides comprehensive solutions across the drug development lifecycle, including drug discovery, pharmaceutical chemistry, formulation development, and clinical trial management. Its core operations focus on high-end generic drug development, innovative drug R&D, and bioequivalence studies. Through its integrated service platform, the company supports the synthesis of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The firm emphasizes technical innovation and quality control to facilitate the commercialization of therapeutic products, leveraging advanced laboratory facilities and a professional technical team.

Recent filings

Filing Released Lang Actions
新疆百花村医药集团股份有限公司关于控股股东、实际控制人协议转让公司股份调整转让价款的公告
Major Shareholding Notification Classification · 85% confidence The document is a Shanghai Stock Exchange corporate announcement (“公告”) detailing the adjustment of the transfer price and payment terms for a 20.68% block of shares originally held by the controlling shareholders. It is not a financial report, management discussion, or earnings release, and it does not involve the company issuing new shares or buying back its own stock. Instead, it notifies the market of a significant change in share ownership and control. This matches the “Major Shareholding Notification” category (MRQ).
2026-05-12 Chinese
新疆百花村医药集团股份有限公司2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is titled as the 2025 Annual General Meeting (AGM) materials for 新疆百花村医药集团股份有限公司. It contains detailed agenda items for the 2025 annual shareholders meeting, including the 2025 Board of Directors work report, profit distribution plan, proposal to reappoint the audit firm for 2026, director remuneration proposals, independent director reports, and audit committee reports. The content is consistent with materials typically prepared and distributed for an AGM to inform shareholders and facilitate voting. The document is lengthy (15,000 characters) and includes detailed reports and proposals but is clearly labeled as meeting materials for the annual shareholders meeting. Therefore, it fits the category of AGM Information (AGM-R). It is not the full Annual Report (10-K) or Audit Report (AR) itself, but rather the meeting materials presented at the AGM. Hence, the classification is AGM-R with high confidence.
2026-04-10 Chinese
新疆百花村医药集团股份有限公司关于全资子公司受让南通勤智健腾创业投资基金份额暨对外投资的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Xinjiang Baihua Village Pharmaceutical Group Co., Ltd. regarding its wholly-owned subsidiary acquiring a 4.75% interest in an investment fund and the progress of this external investment. It details the investment amount, the transfer agreement, changes in the partnership structure of the fund, and states that the transaction will not materially affect the company's financial condition or operations. The document is relatively short (2242 characters) and focuses on a specific investment transaction update rather than comprehensive financial data or results. It does not contain financial statements or detailed financial analysis. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2026-04-10 Chinese
新疆百花村医药集团股份有限公司简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding of significant shareholders in 新疆百花村医药集团股份有限公司, including the transfer of a large block of shares (20.68% of total shares) from existing controlling shareholders to a new controlling shareholder entity. The document includes detailed information about the parties involved, the share transfer agreement, payment terms, legal representations, and other related disclosures. It references compliance with Chinese securities laws and disclosure standards specifically related to equity changes. There is no indication that this is a full annual or interim financial report, audit report, earnings release, or other types of filings. Instead, it is a formal notification and detailed report of a major shareholding change, consistent with the category of "Major Shareholding Notification." The document length and detail confirm it is the report itself, not just an announcement of a report publication. Therefore, the appropriate classification is MRQ (Major Shareholding Notification).
2026-04-09 Chinese
新疆百花村医药集团股份有限公司详式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled "详式权益变动报告书" which translates to "Detailed Equity Change Report". It is issued by 新疆百花村医药集团股份有限公司 and details a significant equity transaction involving a change in controlling shareholder and control rights. The document includes detailed information about the parties involved, shareholding changes, transaction agreements, payment terms, and legal assurances. It references compliance with Chinese securities laws and regulations, including the Shanghai Stock Exchange and China Securities Regulatory Commission. The content is focused on a detailed report of a significant shareholding change, including the acquisition of a 20.68% stake by a new controlling shareholder. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is comprehensive and contains substantive details about the shareholding change, not merely an announcement or a brief summary. Therefore, the appropriate classification is MRQ with high confidence.
2026-04-09 Chinese
国泰海通证券股份有限公司关于新疆百花村医药集团股份有限公司详式权益变动报告书之财务顾问核查意见
Major Shareholding Notification Classification · 95% confidence The document is titled as a "详式权益变动报告书" which translates to a "Detailed Equity Change Report." It includes extensive financial advisor verification opinions, detailed disclosures about the equity change, the parties involved, the purpose of the equity change, the method of equity transfer, and the legal and regulatory compliance aspects. The document references specific regulatory guidelines such as the "上市公司收购管理办法" (Measures for the Administration of Takeovers of Listed Companies), and detailed financial and legal disclosures are provided. The content is focused on a significant equity change involving a controlling stake acquisition in a listed company, with detailed analysis and verification by a financial advisor. This type of document corresponds to a detailed report on a change in major shareholding or equity interest in a listed company. According to the filing definitions, this fits best under "Major Shareholding Notification (Code: MRQ)" which covers notifications of changes in significant share ownership levels crossing thresholds. The document is not a simple announcement but a detailed report with financial advisor opinions and compliance checks, confirming it is the report itself, not just an announcement. Therefore, the correct classification is MRQ with high confidence.
2026-04-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.